Characteristic | n = 258 |
---|---|
Journal type | |
General medical | 118 (46%) |
Specialty | 140 (54%) |
Most common specialties | |
Oncology | 44 (17%) |
Cardiology | 42 (16%) |
Paediatrics | 26 (10%) |
Anaesthesia | 22 (8%) |
Public health | 18 (7%) |
Most common countries where trial was conducted | |
USA | 40 (22%) |
UK | 27 (15%) |
Netherlands | 16 (9%) |
Australia | 4 (2%) |
Not reported | 38 (20%) |
Trial designa | |
Parallel | 225 (86.5%) |
Cluster | 16 (6%) |
Factorial | 11 (4%) |
Crossover | 8 (3%) |
Split-body | 1 (0.5%) |
Intervention | |
Drug | 127 (49%) |
Surgery/procedure | 59 (23%) |
Behavioural/education | 40 (16%) |
Biological/vaccine | 12 (5%) |
Device | 9 (3%) |
Dietary supplement | 6 (2%) |
Other | 5 (2%) |
Study centres | |
Single | 46 (18%) |
Multiple | 191 (74%) |
Unclear | 21 (8%) |
Number of intervention groups | |
2 | 202 (78%) |
3 | 35 (13.5%) |
4 | 20 (8%) |
> 4 | 1 (0.5) |
Median sample size (IQR)b | 325 (138 to 1010) |
10 to 90 percentile | (60 to 2485) |
Primary outcome clearly defined | |
Defined | 238 (92%) |
Not defined | 20 (8%) |
Statistical significance of primary outcome (where defined)c | |
Significant | 116 (49%) |
Non-significant | 122 (51%) |
Trial registration | |
Reported | 235 (91%) |
Not reported | 23 (9%) |
Trial protocol accessible | |
Reported | 141 (55%) |
Not reported | 117 (45%) |
Source of funding | |
Solely industry | 52 (20%) |
Part industry | 27 (10%) |
Non-industry | 159 (62%) |
No funding | 7 (3%) |
Not reported | 13 (5%) |